CA3196582A1 - Bicyclic compounds and uses thereof for the treatment of diseases - Google Patents
Bicyclic compounds and uses thereof for the treatment of diseasesInfo
- Publication number
- CA3196582A1 CA3196582A1 CA3196582A CA3196582A CA3196582A1 CA 3196582 A1 CA3196582 A1 CA 3196582A1 CA 3196582 A CA3196582 A CA 3196582A CA 3196582 A CA3196582 A CA 3196582A CA 3196582 A1 CA3196582 A1 CA 3196582A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- alkyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108660P | 2020-11-02 | 2020-11-02 | |
| US63/108,660 | 2020-11-02 | ||
| PCT/US2021/057563 WO2022094400A1 (en) | 2020-11-02 | 2021-11-01 | Bicyclic compounds and uses thereof for the treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3196582A1 true CA3196582A1 (en) | 2022-05-05 |
Family
ID=81384389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3196582A Pending CA3196582A1 (en) | 2020-11-02 | 2021-11-01 | Bicyclic compounds and uses thereof for the treatment of diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240025903A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4236944A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7884275B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230104191A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116568301A (cg-RX-API-DMAC7.html) |
| AR (1) | AR124637A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021371026A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3196582A1 (cg-RX-API-DMAC7.html) |
| CL (2) | CL2023001195A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL302465A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023004942A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI918751B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022094400A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL313039A (en) * | 2021-12-17 | 2024-07-01 | Athira Pharma Inc | Uses of bicyclic compounds for the treatment of diseases |
| KR20250005323A (ko) * | 2022-05-04 | 2025-01-09 | 아티라 파마, 인코포레이티드 | 신경병증을 치료하는 방법 |
| US20250275976A1 (en) * | 2022-05-04 | 2025-09-04 | Athira Pharma, Inc. | Methods of Treating Neuroinflammatory Conditions |
| JP2025538382A (ja) | 2022-11-18 | 2025-11-28 | アティラ・ファーマ・インコーポレイテッド | 炎症病態を治療する方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184223B1 (en) * | 1995-10-27 | 2001-02-06 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
| WO2004035587A1 (en) | 2002-10-17 | 2004-04-29 | Myriad Genetics, Inc. | Reverse-turn mimetics and composition and methods relating thereto |
| US7192976B2 (en) * | 2002-12-21 | 2007-03-20 | Angion Biomedica Corporation | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| WO2006036981A2 (en) * | 2004-09-28 | 2006-04-06 | Angion Biomedica Corp. | Small molecule modulators of cytokine activity |
| US7879898B1 (en) * | 2006-02-14 | 2011-02-01 | Angion Biomedica Corp. | Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease |
| EP1947085A1 (en) * | 2007-01-19 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Substituted indole sulfonamide compounds, their preparation and use as medicaments |
| US8691819B2 (en) * | 2008-10-14 | 2014-04-08 | Prism Biolab Corporation | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions |
| US20160074400A1 (en) * | 2012-08-06 | 2016-03-17 | University Of Southern California | Wnt modulators for the protection, mitigation and treatment of radiation injury |
| EP3366687B1 (en) * | 2015-09-18 | 2020-04-29 | National University Corporation Tottori University | Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis |
-
2021
- 2021-11-01 AU AU2021371026A patent/AU2021371026A1/en active Pending
- 2021-11-01 EP EP21887720.7A patent/EP4236944A4/en active Pending
- 2021-11-01 US US18/032,918 patent/US20240025903A1/en active Pending
- 2021-11-01 MX MX2023004942A patent/MX2023004942A/es unknown
- 2021-11-01 TW TW110140600A patent/TWI918751B/zh active
- 2021-11-01 JP JP2023551946A patent/JP7884275B2/ja active Active
- 2021-11-01 IL IL302465A patent/IL302465A/en unknown
- 2021-11-01 AR ARP210103033A patent/AR124637A1/es unknown
- 2021-11-01 KR KR1020237018061A patent/KR20230104191A/ko active Pending
- 2021-11-01 CN CN202180079749.8A patent/CN116568301A/zh active Pending
- 2021-11-01 CA CA3196582A patent/CA3196582A1/en active Pending
- 2021-11-01 WO PCT/US2021/057563 patent/WO2022094400A1/en not_active Ceased
- 2021-11-01 CN CN202411623883.1A patent/CN119684295A/zh active Pending
-
2023
- 2023-04-26 CL CL2023001195A patent/CL2023001195A1/es unknown
-
2024
- 2024-02-02 CL CL2024000340A patent/CL2024000340A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4236944A1 (en) | 2023-09-06 |
| TWI918751B (zh) | 2026-03-21 |
| CL2024000340A1 (es) | 2024-08-16 |
| CN116568301A (zh) | 2023-08-08 |
| US20240025903A1 (en) | 2024-01-25 |
| CN119684295A (zh) | 2025-03-25 |
| AU2021371026A1 (en) | 2023-06-15 |
| JP2023550543A (ja) | 2023-12-01 |
| AU2021371026A9 (en) | 2024-04-18 |
| JP7884275B2 (ja) | 2026-07-03 |
| KR20230104191A (ko) | 2023-07-07 |
| AR124637A1 (es) | 2023-04-19 |
| IL302465A (en) | 2023-06-01 |
| CL2023001195A1 (es) | 2023-10-20 |
| TW202233622A (zh) | 2022-09-01 |
| MX2023004942A (es) | 2023-07-06 |
| EP4236944A4 (en) | 2024-09-04 |
| WO2022094400A1 (en) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020413997B2 (en) | Pyridazinyl-thiazolecarboxamide compound | |
| AU2021371026A1 (en) | Bicyclic compounds and uses thereof for the treatment of diseases | |
| EP4598907A1 (en) | Phenyl oxy amide kinase inhibitors | |
| CA3240896A1 (en) | Uses of bicyclic compounds for the treatment of diseases | |
| EP4518866A1 (en) | Methods of treating fibrosis | |
| AU2023263997A1 (en) | Methods of treating neuroinflammatory conditions | |
| EA049703B1 (ru) | Бициклические соединения и их применение для лечения заболеваний | |
| AU2023265053A1 (en) | Methods of treating neuropathies. | |
| EA050745B1 (ru) | Применение бициклических соединений для лечения заболеваний | |
| CN118382441A (zh) | 双环化合物用于治疗疾病的用途 | |
| HK40122844A (en) | Bicyclic compounds and uses thereof for the treatment of diseases | |
| HK40097563A (en) | Bicyclic compounds and uses thereof for the treatment of diseases | |
| HK40113746A (en) | Uses of bicyclic compounds for the treatment of diseases | |
| WO2025250930A1 (en) | Hdac6 inhibitors and method of their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241024 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241024 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241024 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241122 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250922 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250922 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250922 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251020 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251020 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251126 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251126 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251126 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251128 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED Effective date: 20260210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260428 |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260504 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260514 |